Volume 34, Issue 8 p. 1228-1232
Brief Report

How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy

Max-Joseph Grimm

Max-Joseph Grimm

Department of Neurology, Technische Universität München, Munich, Germany

German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

Search for more papers by this author
Gesine Respondek MD

Gesine Respondek MD

Department of Neurology, Technische Universität München, Munich, Germany

German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

Search for more papers by this author
Maria Stamelou MD

Maria Stamelou MD

Second Department of Neurology, Attikon University Hospital, University of Athens, Athens, Greece

Search for more papers by this author
Thomas Arzberger MD

Thomas Arzberger MD

German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universität, Munich, Germany

Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany

Search for more papers by this author
Leslie Ferguson MD

Leslie Ferguson MD

Division of Neurology, Royal University Hospital, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

Search for more papers by this author
Ellen Gelpi MD

Ellen Gelpi MD

Neurological Tissue Bank and Neurology Department, Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, CERCA, Barcelona, Catalonia, Spain

Institute of Neurology, Medical University of Vienna, Vienna, Austria

Search for more papers by this author
Armin Giese MD

Armin Giese MD

Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universität, Munich, Germany

Search for more papers by this author
Murray Grossman MD

Murray Grossman MD

Frontotemporal Degeneration Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Search for more papers by this author
David J. Irwin MD

David J. Irwin MD

Frontotemporal Degeneration Center, Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Search for more papers by this author
Alexander Pantelyat MD

Alexander Pantelyat MD

Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA

Search for more papers by this author
Alex Rajput MD

Alex Rajput MD

Division of Neurology, Royal University Hospital, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

Search for more papers by this author
Sigrun Roeber MD

Sigrun Roeber MD

Center for Neuropathology and Prion Research, Ludwig-Maximilians-Universität, Munich, Germany

Search for more papers by this author
John C. van Swieten MD

John C. van Swieten MD

Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands

Search for more papers by this author
Claire Troakes PhD, MSc

Claire Troakes PhD, MSc

London Neurodegenerative Diseases Brain Bank, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK

Search for more papers by this author
Angelo Antonini MD, PhD

Angelo Antonini MD, PhD

Parkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, and Department of Neurosciences, Padova University, Padova, Italy

Search for more papers by this author
Kailash P. Bhatia MD

Kailash P. Bhatia MD

Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, Queen Square, London, UK

Search for more papers by this author
Carlo Colosimo MD, FEAN

Carlo Colosimo MD, FEAN

Department of Neurology, Santa Maria University Hospital of Terni, Terni, Italy

Search for more papers by this author
Thilo van Eimeren MD

Thilo van Eimeren MD

Departments of Nuclear Medicine and Neurology, University of Cologne, Cologne, Germany

Search for more papers by this author
Jan Kassubek MD

Jan Kassubek MD

Department of Neurology, University of Ulm, Ulm, Germany

Search for more papers by this author
Johannes Levin MD

Johannes Levin MD

German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

Department of Neurology, Ludwig-Maximilians-Universität, Munich, Germany

Search for more papers by this author
Wassilios G. Meissner MD, PhD

Wassilios G. Meissner MD, PhD

Univ. de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France

Service de Neurologie, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France

Dept. Medicine, University of Otago, Christchurch, and New Zealand Brain Research Institute, Christchurch, New Zealand

Search for more papers by this author
Christer Nilsson MD

Christer Nilsson MD

Department of Clinical Sciences, Division of Neurology, Lund University, Lund, Sweden

Search for more papers by this author
Wolfgang H. Oertel MD

Wolfgang H. Oertel MD

Department of Neurology, Philipps Universität, Marburg, Germany

Search for more papers by this author
Ines Piot

Ines Piot

Department of Neurology, Technische Universität München, Munich, Germany

German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

Search for more papers by this author
Werner Poewe MD

Werner Poewe MD

Department of Neurology, Medical University Innsbruck, Innsbruck, Austria

Search for more papers by this author
Gregor K. Wenning MD, PhD

Gregor K. Wenning MD, PhD

Department of Neurology, Medical University Innsbruck, Innsbruck, Austria

Search for more papers by this author
Adam Boxer MD, PhD

Adam Boxer MD, PhD

Memory and Aging Center, Department of Neurology, University of California, San Francisco, California, USA

Search for more papers by this author
Lawrence I. Golbe MD

Lawrence I. Golbe MD

Department of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA

Search for more papers by this author
Keith A. Josephs MD, MST, MSc

Keith A. Josephs MD, MST, MSc

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA

Search for more papers by this author
Irene Litvan MD

Irene Litvan MD

Department of Neurology, University of California, San Diego, California, USA

Search for more papers by this author
Huw R. Morris MD

Huw R. Morris MD

Department of Clinical Neuroscience, UCL Institute of Neurology, Queen Square, London, UK

Search for more papers by this author
Jennifer L. Whitwell PhD

Jennifer L. Whitwell PhD

Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA

Search for more papers by this author
Yaroslau Compta MD

Yaroslau Compta MD

Parkinson's Disease & Movement Disorders Unit, Hospital Clínic/IDIBAPS/CIBERNED/European Reference Network for Rare Neurological Diseases (ERN-RND)/Institut de Neurociències, Universitat de Barcelona, Barcelona, Catalonia, Spain

Search for more papers by this author
Jean-Christophe Corvol MD, PhD

Jean-Christophe Corvol MD, PhD

Sorbonne Université, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, ICM, Hôpital Pitié-Salpêtrière, Department of Neurology, Paris, France

Search for more papers by this author
Anthony E. Lang MD

Anthony E. Lang MD

The Edmond J Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada

Search for more papers by this author
James B. Rowe MD

James B. Rowe MD

Department of Clinical Neurosciences and Cambridge Centre for Parkinson-Plus, Cambridge University, Cambridge, UK

Search for more papers by this author
Günter U. Höglinger MD

Corresponding Author

Günter U. Höglinger MD

Department of Neurology, Technische Universität München, Munich, Germany

German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

Correspondence to: Prof. Dr. Günter U. Höglinger, Dept. of Translational Neurodegeneration, German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen Str. 17, D-81677 Munich, Germany. Phone: +49-89-4400-46464, Fax: +49-89-4400-46565; E-mail: [email protected].Search for more papers by this author
for the Movement Disorder Society-endorsed PSP Study Group

for the Movement Disorder Society-endorsed PSP Study Group

Search for more papers by this author
First published: 18 March 2019
Citations: 83
Max-Joseph Grimm and Gesine Respondek contributed equally to this article.

Relevant conflicts of interest/financial disclosures: None.

Funding agencies: The project was supported by the Bischof Dr. Karl Golser Stiftung, CurePSP, Deutsche Forschungsgemeinschaft (DFG, HO 2402/11-1), German Center for Neurodegenerative Diseases e.V. (DZNE), German PSP Gesellschaft, Tau Consortium, UK PSP Association, and the International Parkinson & Movement Disorder Society.

Abstract

Background

The Movement Disorder Society criteria for progressive supranuclear palsy define diagnostic allocations, stratified by certainty levels and clinical predominance types. We aimed to study the frequency of ambiguous multiple allocations and to develop rules to eliminate them.

Methods

We retrospectively collected standardized clinical data by chart review in a multicenter cohort of autopsy-confirmed patients with progressive supranuclear palsy, to classify them by diagnostic certainty level and predominance type and to identify multiple allocations.

Results

Comprehensive data were available from 195 patients. More than one diagnostic allocation occurred in 157 patients (80.5%). On average, 5.4 allocations were possible per patient. We developed four rules for Multiple Allocations eXtinction (MAX). They reduced the number of patients with multiple allocations to 22 (11.3%), and the allocations per patient to 1.1.

Conclusions

The proposed MAX rules help to standardize the application of the Movement Disorder Society criteria for progressive supranuclear palsy. © 2019 International Parkinson and Movement Disorder Society